Ignite Creation Date:
2024-05-06 @ 6:15 PM
Last Modification Date:
2024-10-26 @ 2:44 PM
Study NCT ID:
NCT05596266
Status:
RECRUITING
Last Update Posted:
2022-10-27
First Post:
2022-10-23
Brief Title:
CD5 CAR-T Therapy for RefractoryRelapsed CD5 T-cell Acute Lymphoblastic Leukemia
Sponsor:
Xuanwu Hospital Beijing
Organization:
Xuanwu Hospital Beijing
Study Overview
Official Title:
A Phase I Study of CD5 CAR-T for RefractoryRelapsed CD5 T-ALL Patients
Status:
RECRUITING
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase I interventional single arm open label clinical study to evaluate the safety and tolerability of CD5 CAR-T cells in refractoryrelapsed CD5 T-ALL patients who have no available curative treatment options
Detailed Description:
T-acute lymphoblast leukemia T-ALL is a neoplastic lymphoid leukemia characterized by the proliferation of immature precursor T cells The combined chemotherapy has significantly improved the prognosis of T-acute lymphoblast leukemialymphoma However once the disease appears to be relapsedrefractory there is limited treatment options and the overall prognosis is extremely poor Therefore exploring safe and effective treatments is a critical unmet medical need The patients will receive infusion of CAR T-cells targeting CD5 to examine the safety and possibly the efficacy of CD5 CAR T-Cells in CD5 relapsed or refractory acute leukemia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None